125
Participants
Start Date
October 31, 2013
Primary Completion Date
March 27, 2018
Study Completion Date
March 27, 2018
Circadin 2/5/10 mg
Circadin 2/5/10 mg. Active arm
Placebo
Control arm
Geinsinger Clinic, Danville
Kennedy Krieger Institute, Baltimore
Lake Mary Pediatrics, Orange City
Ericksen Research & Development, Clinton
Crystal BioMedical Research, LLC, Miami Lakes
Mate Lazlo, West Palm Beach
Vanderbilt University, Nashville
AMR Baber research INC, Naperville
INSITE Clinical Research, DeSoto
Red Oak Psychiatry Associates, Houston
Sleep Therapy & Research Center, San Antonio
Road Runner Research, Ltd, San Antonio
Southwest Autism Research and Resource Center (SARRC), Phoenix
Child Neurology Specialists/ CRCN, Henderson
Pacific institute of medical science, Bothell
Attalla Consultants LLC, dba Institue for Behabiovral medicine, Smyrna
Clinical research center of New Jersey, LLC, Voorhees Township
The children's hospital of Philadelphia, Philadelphia
Helsinki Sleep Clinic Vitalmed OY, Helsinki
Hospital Raymond Poincare, Garches
Strasbourg University Hospital Depatment of Child Psychiatry & Neurology, Strasbourg
Yulius Mental Health Organization, Dordrecht
Hospital Gelderse Vallei, Ede
University Medical Center Groningen, Groningen
Birmingham Childrens Hospital NHS FOUNDATION TRUST, Birmingham
Blackpool Victoria Teaching Hospitals NHS Foundation Trust, Blackpool
Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital, London
University Hospital Southampton NHS Foundation Trust, Southampton
Lead Sponsor
Neurim Pharmaceuticals Ltd.
INDUSTRY